KR-402

KR-402 is an in vivo CAR-T: mRNA in T-cell-targeted lipid nanoparticles from Kernal Biologics. A programme that uses T-cell-targeted lipid nanoparticles carrying mRNA to programme CAR-T cells directly inside the body; the company reports B-cell depletion within a week. Its furthest stage is preclinical development, for cancer. No clinical trial naming it is registered on ClinicalTrials.gov. No registered trial found on ClinicalTrials.gov for KR-402 or KR402 (checked 3 Nov 2026). The CAR target antigen is not stated in any source read. It has not been shown to work in people.